VaxGen announced in May 2005 that it would fund proof-of-concept studies and then determine whether to pursue commercial development of the vaccine candidate.
The initial proof-of-concept phase was undertaken jointly by EndoBiologics and VaxGen, with VaxGen providing research funding and conducting preclinical testing of the vaccine candidate.
“Although we do not wish to pursue commercial development of this product, we will continue to look for other opportunities to develop a vaccine candidate against meningitis B,” said Dr Lance Gordon, VaxGen’s president and CEO.
VaxGen, is a biopharmaceutical company engaged in the development, manufacture and commercialization of biologic products for the prevention and treatment of human infectious diseases, including anthrax and smallpox.